Si-yu Wu

Key Laboratory Of Breast Cancer In Shanghai
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer.

DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer.

Journal: Med (New York, N.Y.)

Published: March 10, 2024

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.

Journal: International journal of surgery (London, England)

Published: November 27, 2022

Repeated core needle biopsy and targeted fine-needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: prospective clinical study.

Repeated core needle biopsy and targeted fine-needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: prospective clinical study.

Journal: The British journal of surgery

Published: November 13, 2022

Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: prospective feasibility study.

Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: prospective feasibility study.

Journal: The British journal of surgery

Published: May 17, 2022

Prior Local or Systemic Treatment: A Predictive Model Could Guide Clinical Decision-Making for Locoregional Recurrent Breast Cancer.

Prior Local or Systemic Treatment: A Predictive Model Could Guide Clinical Decision-Making for Locoregional Recurrent Breast Cancer.

Journal: Frontiers in oncology

Published: October 09, 2021

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.

Journal: Journal for immunotherapy of cancer

Published: June 27, 2021

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.

Journal: Journal for immunotherapy of cancer

Published: May 30, 2021

Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Journal: Translational cancer research

Published: May 26, 2019

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.

Journal: Cancer

Published: October 22, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026